Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia

Corebinding factor acute myeloid leukemia (CBF-AML) is the most common cytogenetic subtype of pediatric AML. CBF-AML is associated with a relatively favorable outcome, although the relapse rate of approximately 40% indicates a high degree of clinical heterogeneity. The clinical impact of additional cytogenetic aberrations, including c-KIT and CEBPA mutations, in pediatric CBF-AML has not been well characterized, especially in the multi-ethnic region of Yunnan Province in China.

Source: Pediatrics and Neonatology - January 25, 2023 Category: Perinatology & Neonatology Authors: Xiaoyan Mao, Runxiu Yin, Li Liu, Yan Zhou, Chunhui Yang, Chunlian Fang, Hongchao Jiang, Qulian Guo, Xin Tian Tags: Original Article Source Type: research